Literature DB >> 4854257

Serum concentration and half-life of rifampicin after simultaneous oral administration of aminosalicylic acid or isoniazid.

G Boman.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4854257     DOI: 10.1007/bf00560384

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  23 in total

1.  Assay of antibiotics in small amounts of fluid.

Authors:  H ERICSSON
Journal:  Scand J Clin Lab Invest       Date:  1960       Impact factor: 1.713

Review 2.  Factors affecting gastrointestinal absorption of drugs.

Authors:  R R Levine
Journal:  Am J Dig Dis       Date:  1970-02

3.  Kinetic studies on rifampicin. I. Serum concentration analysis in subjects treated with different oral doses over a period of two weeks.

Authors:  G Acocella; V Pagani; M Marchetti; G C Baroni; F B Nicolis
Journal:  Chemotherapy       Date:  1971       Impact factor: 2.544

4.  [Experimental study on rifamicin pharmacodynamics].

Authors:  G Curci; A Ninni; F Di Mezza
Journal:  Arch Tisiol Mal Appar Respir       Date:  1968-04

5.  [Level of rifampicine in human serum].

Authors:  G Porven; G Canetti
Journal:  Rev Tuberc Pneumol (Paris)       Date:  1968 Jul-Aug

6.  Inactivation of isoniazid (INH) in Swedish tuberculous patients before and during treatment with para-aminosalicylic acid (PAS).

Authors:  A Hanngren; O Borgå; F Sjöqvist
Journal:  Scand J Respir Dis       Date:  1970

7.  [Icterigenic hepatitis during the treatment with combined isoniazid and rifampicin. Clinical and experimental observations].

Authors:  J Marche; F C Hugues; B Graisely; C Marche
Journal:  Rev Tuberc Pneumol (Paris)       Date:  1971 Jan-Feb

8.  Effect of rifampicin and isoniazid on liver function.

Authors:  S Lal; S N Singhal; D M Burley; G Crossley
Journal:  Br Med J       Date:  1972-01-15

9.  [Comparative study of the development of rifomycin blood levels in humans by 2 different microbiologic methods].

Authors:  G Canetti; V Djurovic; M Le Lirzin; R Thibier; A Lepeuple
Journal:  Rev Tuberc Pneumol (Paris)       Date:  1970

10.  Changes of the smooth endoplasmic reticulum induced by rifampicin in human and guinea-pig hepatocytes.

Authors:  A M Jezequel; F Orlandi; L T Tenconi
Journal:  Gut       Date:  1971-12       Impact factor: 23.059

View more
  18 in total

1.  Mechanism of the inhibitory effect of PAS granules on the absorption of rifampicin: adsorption of rifampicin by an excipient, bentonite.

Authors:  G Boman; P Lundgren; G Stjernström
Journal:  Eur J Clin Pharmacol       Date:  1975-06-13       Impact factor: 2.953

2.  Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance.

Authors:  W Zilly; D D Breimer; E Richter
Journal:  Eur J Clin Pharmacol       Date:  1975-12-19       Impact factor: 2.953

3.  Serum concentrations and bioavailability of rifampicin and isoniazid in combination.

Authors:  J C Garnham; T Taylor; P Turner; L F Chasseaud
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

Review 4.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

5.  Binding of rifampicin by human plasma proteins.

Authors:  G Boman; V A Ringberger
Journal:  Eur J Clin Pharmacol       Date:  1974-08-23       Impact factor: 2.953

6.  Pharmacokinetics of oral and intravenous rifampicin during chronic administration.

Authors:  U Loos; E Musch; J C Jensen; G Mikus; H K Schwabe; M Eichelbaum
Journal:  Klin Wochenschr       Date:  1985-12-02

Review 7.  Clinical pharmacokinetic considerations in the treatment of patients with leprosy.

Authors:  K Venkatesan
Journal:  Clin Pharmacokinet       Date:  1989-06       Impact factor: 6.447

8.  Effect of prednisolone and rifampin on isoniazid metabolism in slow and rapid inactivators of isoniazid.

Authors:  G R Sarma; S Kailasam; N G Nair; A S Narayana; S P Tripathy
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

9.  Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide.

Authors:  J Dhillon; J M Dickinson; K Sole; D A Mitchison
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

Review 10.  Clinical pharmacokinetics of rifampicin.

Authors:  G Acocella
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.